Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).
Here are several LD deals that have been recently publicly confirmed subsequent to the approvals.
AllianceRx Walgreens Pharmacy will now distribute two medications indicated for adults with certain types of lymphoma
Lunsumio from Genentech is used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more lines of systemic therapy for their cancer.
Jaypirca from Eli Lilly treats adults with mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment, and who have already received two or more lines of systemic therapy for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine.
——————————————-
Orsini Specialty Pharmacy will distribute topical gene therapy Vyjuvek
Orsini Specialty Pharmacy announced that Krystal Biotech has selected it as part of the limited specialty pharmacy network for Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for the treatment of Dystrophic Epidermolysis Bullosa (DEB).
——————————————-
Option Care Health will distribute topical gene therapy Vyjuvek to include vials and pre-mixed therapy direct to health care providers
Option Care Health announced that it was selected by Krystal Biotech as part of a limited distribution specialty pharmacy network for Vyjuvek. Further, Option Care will serve as the only specialty pharmacy provider for mixing and delivering prepared Vyjuvek gel administration syringes to professional health care and home settings.
